← Issue №10/ week of Sep 6, 2026/Hepatology

Gene-Based Clustering Identifies QSOX1 and IL1RAP as Biomarkers of Metabolic Dysfunction-Associated Steatotic Liver Disease.

From GI Signals issue №10: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology prospective cohort · n=625 · Sep 1, 2026 · Liver International · IF 6.7

Gene-Based Clustering Identifies QSOX1 and IL1RAP as Biomarkers of Metabolic Dysfunction-Associated Steatotic Liver Disease.

Diagnosticbiomarkerbasic sciencetranslationalepidemiology
Clinical takeawayNo clinical action yet: a preclinical biomarker finding requiring validation in prospective human studies before clinical use.
What it foundQSOX1/IL1RAP plasma ratio had AUROC 0.95 for MASLD diagnosis by proteomics and 0.82 by ELISA, correlating with disease severity.
ContextIdentifies potential non-invasive biomarkers for MASLD, a condition currently diagnosed via imaging or biopsy, but these markers are not yet validated for clinical practice.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Ma W … Lin L · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
← Read the whole of issue №10 Every paper GI Signals surfaces gets a page like this one. All issues